CCL Products (India) Limited
Momentum (78/100) does the heavy lifting; valuation (6/100) is the drag.
ExpensiveOvervaluedOur blended model reads CCL Products (India) Limited as a Hold at 45/100. We put fair value near ₹748.65; at ₹1,198.6 that leaves roughly 38% downside, so the stock screens overvalued by 38%. On 40.1x trailing earnings it sits pricier than the Consumer Defensive median of about 26.1x. It's trading right at its 52-week high of ₹1,229.7. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9. The average analyst target of ₹1,279.82 implies about 7% upside across 11 analysts. It clears 8 of 13 investability checks, with durability 54, valuation 11 and momentum 78 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹598.92.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-2.53% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 8/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 18.0%
- Fail: Low debt (D/E < 0.5): 0.56x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 46%
- Pass: Earnings growing: 12%
- Fail: Net margin ≥ 10%: 8.7%
- Fail: Current ratio > 1.5: 1.49
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.44
- Pass: Piotroski ≥ 7: 8/9
Quarterly results
Annual financials
Shareholding
- Promoter49.2%
- Institutions26.1%
- Public & other24.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (18.0%).
- Trading near its 52-week high.
- Financially solid — Altman Z 6.44.
- High Piotroski quality score (8/9).
Opportunities
- Revenue growing (46% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~38% above our estimated fair value.
About CCL Products (India) Limited
CCL Products manufactures and sells instant coffee and coffee-related products in India under the Continental brand, including filter coffee, premix coffee, instant coffee, flavored coffee, spray dried coffee powder, agglomerated coffee, freeze dried coffee, freeze concentrated liquid coffee, roast and ground coffee, and roasted coffee beans. The company also exports its products.
CCL Products (India) Limited — frequently asked questions
Is CCL Products (India) Limited a buy, hold or sell?
StocksWizard currently rates CCL Products (India) Limited (CCL) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is CCL Products (India) Limited's fair value?
Our blended DCF and relative-valuation model estimates CCL Products (India) Limited's fair value at about ₹748.65, versus a current price of ₹1,198.6 — roughly 38% downside. On that basis the stock looks overvalued by 38%.
Is CCL Products (India) Limited financially healthy?
CCL Products (India) Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9.
How has CCL Products (India) Limited's share price performed?
CCL Products (India) Limited is up 6% over three months, and last traded at ₹1,198.6. Past performance doesn't predict future returns.
More in Consumer Defensive
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.